Rigel Pharmaceuticals at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Rigel Pharmaceuticals exhibits at Booth 613 at ASH 2026 in New Orleans. Rigel Pharmaceuticals supports symposia on treatment decisions in acute myeloid leukemia. Its program includes an expert debate on frontline therapy, targeted agents and the order in which to use them, alongside a second-opinion review of patient cases.
| Organization | ASH 2026 Attendance |
|---|---|
Rigel Pharmaceuticals South San Francisco, CA | |
Biotech developing and selling therapies for blood disorders and cancer, with three FDA-approved products including fostamatinib and olutasidenib. | Booth Exhibiting at Booth 613 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. |
Instantly find 20 buyers from Rigel Pharmaceuticals
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction